Loflazepic acid | 71735-10-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯二氮卓类
• 英文名称: Loflazepic acid
• 英文别名: 7-chloro-5-(2-fluorophenyl)-2-oxo-1,3-dihydro-1,4-benzodiazepine-3-carboxylic acid
• CAS: 71735-10-9
• 化学式: C₁₆H₁₀ClFN₂O₃
• 分子量: 332.71
• InChiKey: AUMAPAHSHLMFGL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  23
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  78.8
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• Abuse-proofed dosage form
  申请人：GRÜNENTHAL GMBH

  公开号：US10058548B2

  公开（公告）日：2018-08-28

  The invention relates to a dosage form that is thermoformed without discoloration and is safeguarded from abuse, comprising at least one synthetic or natural polymer having a breaking strength of at least 500 N in addition to one or more active substances that could be subject to abuse. The invention also relates to a corresponding method for producing said dosage form.

  本发明涉及一种热成型而不变色并可防止滥用的剂型，它包括至少一种断裂强度至少为 500 N 的合成或天然聚合物，以及一种或多种可能被滥用的活性物质。本发明还涉及生产上述剂型的相应方法。
• Process for the production of an abuse-proofed dosage form
  申请人：GRÜNENTHAL GMBH

  公开号：US10729658B2

  公开（公告）日：2020-08-04

  The present invention relates to a process for the production of an abuse-proofed dosage form containing, apart from one or more active ingredients with potential for abuse and optionally physiologically acceptable auxiliary substances, at least one synthetic or natural polymer (C) with a breaking strength of at least 500 N, wherein the formulation mixture is combined with a solvent for the polymer (C) at least in quantities such that the formulation mixture is at least uniformly moistened, the at least moistened composition is optionally divided into sub-portions, dried and shaped to yield the dosage form.

  本发明涉及一种防滥用剂型的生产工艺，该剂型除含有一种或多种可能被滥用的活性成分和可选的生理上可接受的辅助物质外，还含有至少一种断裂强度至少为 500 N 的合成或天然聚合物（C），其中制剂混合物与聚合物（C）的溶剂至少按一定量混合，使制剂混合物至少均匀湿润，至少湿润的组合物可选地被分成若干小份，干燥并定型，以得到该剂型。
• Abuse-safeguarded dosage form
  申请人：Bartholomaeus Johannes

  公开号：US20050214223A1

  公开（公告）日：2005-09-29

  A pharmaceutical dosage form that is safeguarded against abuse containing at least one active substance that is susceptible to abuse and at least two of the following constituents (a) through (d): (a) at least one substance that irritates the nasal and/or pharyngeal region; (b) at least one viscosity increasing agent that together with a required minimum quantity of an aqueous liquid forms a gel in an extract obtained from the dosage form, which gel can still be discerned after being introduced into an additional quantity of aqueous liquid; (c) at least one antagonist for the at least one active substance that is susceptible to abuse; and (d) at least one emetic.

  一种防止滥用的药物剂型，含有至少一种易被滥用的活性物质和至少两种以下成分(a)至(d)：(a) 至少一种刺激鼻腔和/或咽部的物质； (b) 至少一种增粘剂，与所需最低量的水性液体一起在从该剂型中提取的萃取液中形成凝胶，这种凝胶在加入额外量的水性液体后仍可辨认； (c) 至少一种易滥用的活性物质的拮抗剂；以及 (d) 至少一种催吐剂。
• Process for the production of an abuse-proofed solid dosage form
  申请人：Arkenau Elisabeth

  公开号：US20050236741A1

  公开（公告）日：2005-10-27

  The present invention relates to a process for the production of an abuse-proofed solid dosage form containing at least one active ingredient with potential for abuse and a binder with a breaking strength of =500 N, by exposing a mixture comprising the active ingredient and the binder to ultrasound and force.

  本发明涉及一种生产防滥用固体制剂的工艺，该制剂含有至少一种可能被滥用的活性成分和断裂强度=500 N 的粘合剂，其方法是将包含活性成分和粘合剂的混合物置于超声波和力的作用下。
• GEGEN MISSBRAUCH GESICHERTE DARREICHUNGSFORM
  申请人：Grünenthal GmbH

  公开号：EP1515702B1

  公开（公告）日：2008-10-15